OpenAI’s No. 2 Bows Out: Chronic Illness Collides With AGI Ambitions and IPO Pressure

• 2019–2024: A rising star with a hidden condition
• April 2026: Medical leave exposes a longer battle
• May–July 2026: Corporate reorg meets personal limits
• July 9, 2026: Stepping down from OpenAI’s No. 2 role

OpenAI’s No. 2 Bows Out: Chronic Illness Collides With AGI Ambitions and IPO Pressure
OpenAI’s carefully constructed leadership structure has been upended just as the company races rivals and eyes a possible IPO, after its No. 2 executive, Fidji Simo, chose health over one of the most powerful jobs in AI.

§2019–2024: A rising star with a hidden condition

Simo was diagnosed in 2019 with postural tachycardia syndrome (POTS), a disorder of the autonomic nervous system that can cause “dizziness or fainting” when people stand because “not enough blood flows back to the heart.” The condition, more common in women aged 15–50, is chronic and incurable, often following major events like surgery, pregnancy, or viral illness.

After more than a decade at Meta and leading Instacart through its 2023 IPO, Simo joined OpenAI’s board in 2024 and, in May 2025, became CEO of Applications, consolidating business and product operations under her while CEO Sam Altman focused on research, compute, and safety.

§April 2026: Medical leave exposes a longer battle

In April 2026, Simo took medical leave following “a severe exacerbation of a chronic illness I’ve lived with for seven years,” she wrote on X, saying it became clear “the road to recovery would be much longer and more complex than I had anticipated—and that I needed to focus on it fully.” Around the same time, COO Brad Lightcap moved to “special projects” and CMO Kate Rouch stepped back to focus on cancer recovery, joining a cluster of health‑related C‑suite changes.

§May–July 2026: Corporate reorg meets personal limits

While Simo was on leave, president Greg Brockman led a May reorganization to prioritize OpenAI’s AI agent strategy, merging products “to invest in a single agentic platform and to merge ChatGPT and Codex into one unified agentic experience for all.”

At the same time, commercial pressure intensified. Simo had been charged with turning costly models into a sustainable business as OpenAI “found itself trailing rival Anthropic” for lucrative enterprise customers, even as both firms neared trillion‑dollar valuations and contemplated IPOs. She reportedly pushed a sharp focus on productivity, warning staff, “We cannot miss this moment because we are distracted by side quests,” before OpenAI shut down its Sora video app and poured resources into coding tools to catch Anthropic’s Claude Code.

§July 9, 2026: Stepping down from OpenAI’s No. 2 role

On July 9, Simo told staff she would leave her full‑time post and transition to a part‑time advisory role after her leave proved “longer and harder than expected,” The Wall Street Journal first reported. She then shared the news publicly, writing that it had been “a jarring experience to spend my days helping build the future while simultaneously navigating a disabling disease that still has no cure.”

Altman responded on X: “i am really sad about this and very grateful for all fidji has done for openai… we all wish her the best for a speedy recovery. this sucks.”

Her exit leaves Altman seeking a successor at a pivotal time: ChatGPT’s growth has cooled, internal revenue targets were missed, and OpenAI is leaning harder into developer tools while “trailing Anthropic” in key areas. Simo had been widely viewed as a leading candidate to assume even more responsibility post‑IPO, making her health‑driven step back both a deeply personal decision and a strategic blow for a company trying to “build the future” at breakneck speed.

Continue reading https://foxvector.com/stories/019f6191-ca78-0d88-70cf-076beb0cc37b